2022
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
Ragon B, D'Souza A, Estrada-Merly N, Fraser R, George G, Gowda L, Shah N, Qazilbash M, Kumar S, Horowitz M, Usmani S, Shah M. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. Journal Of Clinical Oncology 2022, 40: 8057-8057. DOI: 10.1200/jco.2022.40.16_suppl.8057.Peer-Reviewed Original ResearchSecond hematological malignanciesSecond primary malignanciesTherapy-related myeloid neoplasmsOverall survivalMultiple myelomaAllogeneic HCTMaintenance therapyDevelopment of SPMsAutologous hematopoietic stem cell transplantMarrow Transplant Research registryThree-year cumulative incidenceHematopoietic stem cell transplantHematopoietic stem cell transplantationMelphalan conditioning regimenMedian overall survivalStem cell transplantStem cell transplantationAuto-HCTCIBMTR analysisInferior PFSMedian followAllo-SCTCommonest causeConditioning regimenKarnofsky score
2021
575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Perreault S, Schiffer M, Gowda L, Foss F, Isufi I, Seropian S. 575 Application of Pharmacogenomic Guided Immunosuppression Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Transplantation And Cellular Therapy 2021, 27: s461. DOI: 10.1016/s2666-6367(21)00600-x.Peer-Reviewed Original Research
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weeklyClinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplantPredictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.Peer-Reviewed Original ResearchRelapse-free survivalPET-CT scanTime of SCTTime of alloSCTPET-CTT-NHLBM biopsyAllo-SCTCT scanPositive PET/CT scanPredictive valueLong-term relapse-free survivalPositive PET-CT scanAllogeneic stem cell transplantPeripheral blood flow cytometryPET/CT scansIntermediate-high riskBlood flow cytometryAggressive clinical courseStem cell transplantT-cell lymphomaMajority of ptsPositive PET-CTAuto-SCTMedian follow
2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research In Translational Medicine 2019, 67: 51-55. PMID: 30683577, PMCID: PMC7735254, DOI: 10.1016/j.retram.2019.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAgedCytomegalovirusCytomegalovirus InfectionsFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA-DP AntigensHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesRetrospective StudiesRisk FactorsTransplant RecipientsTransplantation ImmunologyTransplantation, HomologousVirus ActivationYoung AdultConceptsHLA-DPB1 mismatchingCMV reactivationOverall survivalRisk of aGVHDRisk of relapseCMV serostatusHLA-DPIncrease riskAllogeneic hematopoietic stem cell transplantationAllogeneic stem cell transplantHematopoietic stem cell transplantationMD Anderson Cancer CenterGVHD target tissuesHLA-DP mismatchesRecipient CMV serostatusRisk of GVHDStem cell transplantStem cell transplantationHLA-DP moleculesAnderson Cancer CenterGVHD incidenceCumulative incidenceCell transplantMultivariable analysisCancer Center
2018
Hepatosplenic T-Cell Lymphomas
Gowda L, Foss F. Hepatosplenic T-Cell Lymphomas. Cancer Treatment And Research 2018, 176: 185-193. PMID: 30596219, DOI: 10.1007/978-3-319-99716-2_9.Peer-Reviewed Original ResearchConceptsHepatosplenic T-cell lymphomaT-cell lymphomaPeripheral T-cell lymphomaHematopoietic stem cell transplantExtranodal peripheral T-cell lymphomaLimited salvage optionsYear of diagnosisAggressive disease courseBone marrow involvementStem cell transplantEligible patientsMarrow involvementPerformance statusPost chemotherapyDisease courseImmune dysregulationProlong remissionSalvage optionCell transplantClinical manifestationsTherapeutic armamentariumLethal outcomeAggressive phenotypeFourth decadeModest responsePrimary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs
Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplantation 2018, 54: 1089-1093. PMID: 30446740, PMCID: PMC8393277, DOI: 10.1038/s41409-018-0392-1.Peer-Reviewed Original ResearchConceptsPrimary plasma cell leukemiaStem cell transplantMultiple myelomaCell transplantPost-autologous stem cell transplantAutologous stem cell transplantPoor long-term survivalPlasma cell leukemiaLong-term survivalInduction drugsCytotoxic chemotherapyAggressive variantTreatment algorithmNovel agentsCell leukemiaOutcomes postNovel drugsTransplantDrugsPosttransplantChemotherapyMyelomaTherapyLeukemia